QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety/tolerability of indacaterol
and glycopyrronium (QVA149) (fixed-dose combination) with fluticasone/salmeterol over a
26-week period in patients with moderate to severe COPD.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Glycopyrrolate Salmeterol Xinafoate Xhance